Key facts
- This page summarizes Michael John Tomsicek's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2021, 20:00.
Michael John Tomsicek - 06 Aug 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRSP
- Reported as of
- 06 Aug 2021
- Net transaction value
- -$3,019,176
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2021, 20:00:31 UTC
- Prior SEC filing
- 29 Jul 2021
- Next SEC filing
- 11 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Esposito, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael John Tomsicek filed Form 4 for CRISPR Therapeutics AG (CRSP) on 10 Aug 2021.
Change
- Previous filing in this sequence was filed on 29 Jul 2021.
- Current net transaction value: -$3,019,176.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- $443,750
- Shares
- +25,000
- Change %
- +1322%
- Price
- $17.75
- Shares after
- 26,891
- Date
- 06 Aug 2021
- Ownership
- Direct
CRSP
transaction
Common Shares
Sale
- Transaction value
- $2,627,700
- Shares
- -19,011
- Change %
- -71%
- Price
- $138.22
- Shares after
- 7,880
- Date
- 06 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
CRSP
transaction
Common Shares
Sale
- Transaction value
- $835,226
- Shares
- -5,989
- Change %
- -76%
- Price
- $139.46
- Shares after
- 1,891
- Date
- 06 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -16%
- Price
- $0.000000
- Shares after
- 131,000
- Date
- 11 Mar 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 25,000
- Exercise price
- $17.75
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F4
This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.